BioCentury | Jan 6, 2014
Clinical News

SAN-300: Phase IIa started

...every other week. Santarus gained exclusive, worldwide rights to SAN-300 through its 2010 acquisition of Covella Pharmaceuticals Inc....
BioCentury | Dec 9, 2013
Clinical News

SAN-300: Phase I data

...with active RA. Santarus gained exclusive, worldwide rights to SAN-300 through its 2010 acquisition of Covella Pharmaceuticals Inc....
BioCentury | Mar 14, 2011
Clinical News

SAN-300: Phase I started

...and RA patients. Santarus gained exclusive, worldwide rights to SAN-300 through its 2010 acquisition of Covella Pharmaceuticals Inc....
BioCentury | Sep 20, 2010
Company News

Covella Pharmaceuticals Inc., Biogen Idec, Santarus deal

...the compound to treat rheumatoid arthritis (RA) in patients who have previously failed anti-TNF therapy. Covella Pharmaceuticals Inc....
Items per page:
1 - 4 of 4
BioCentury | Jan 6, 2014
Clinical News

SAN-300: Phase IIa started

...every other week. Santarus gained exclusive, worldwide rights to SAN-300 through its 2010 acquisition of Covella Pharmaceuticals Inc....
BioCentury | Dec 9, 2013
Clinical News

SAN-300: Phase I data

...with active RA. Santarus gained exclusive, worldwide rights to SAN-300 through its 2010 acquisition of Covella Pharmaceuticals Inc....
BioCentury | Mar 14, 2011
Clinical News

SAN-300: Phase I started

...and RA patients. Santarus gained exclusive, worldwide rights to SAN-300 through its 2010 acquisition of Covella Pharmaceuticals Inc....
BioCentury | Sep 20, 2010
Company News

Covella Pharmaceuticals Inc., Biogen Idec, Santarus deal

...the compound to treat rheumatoid arthritis (RA) in patients who have previously failed anti-TNF therapy. Covella Pharmaceuticals Inc....
Items per page:
1 - 4 of 4